Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer

Abstract Background Therapy targeted to the human epidermal growth factor receptor type 2 (HER2) is used in combination with cytotoxic therapy in treatment of HER2+ breast cancer. Trastuzumab, a monoclonal antibody that targets HER2, has been shown pre-clinically to induce vascular changes that can...

Full description

Bibliographic Details
Published in:BMC Cancer
Main Authors: Meghan J. Bloom, Angela M. Jarrett, Todd A. Triplett, Anum K. Syed, Tessa Davis, Thomas E. Yankeelov, Anna G. Sorace
Format: Article
Language:English
Published: BMC 2020-04-01
Subjects:
Angiogenesis
Tumor associated macrophages
Herceptin
Trastuzumab
BT474
Online Access:http://link.springer.com/article/10.1186/s12885-020-06868-4

Internet

http://link.springer.com/article/10.1186/s12885-020-06868-4

Similar Items